about
Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism.Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS.Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule Are Induced by Ionizing Radiation on Lymphatic Endothelium.Intratumoral Delivery of Immunotherapy-Act Locally, Think Globally.Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies.Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy.Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB).Cytokines in clinical cancer immunotherapyA randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasisTGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal AntibodiesImmunotherapeutic effects of intratumoral nanoplexed poly I:CApoptotic caspases cut down the immunogenicity of radiationApoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patientsTime for radioimmunotherapy: an overview to bring improvements in clinical practiceInternational Symposium: Trailblazing in Cancer Immunotherapy, October 29-31, 2017, Pamplona, SpainNeoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastomaProphylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapyAnti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?
P50
Q36597479-44BBB693-5E9C-4CEA-BC61-C13B57D5FAA2Q38576510-73AC246E-44E6-4CED-9676-DFC5137BEBEAQ38698632-512ABC04-351E-45F6-97EA-B66BEBC77B35Q38722331-4D680925-4906-45A8-A03C-EBBFD203699BQ39043844-4FBC2C8F-DF1E-483E-88B8-5CB5ED63FDFDQ40393934-D1BE035C-84E7-4E0A-A1D7-CE248D580FBFQ50198702-F0947030-7068-4471-8BA4-69D81F0376E2Q50200791-09215E10-182E-4968-B40B-B8238CE84F57Q50420978-E4595111-B61A-44C7-AE45-90A3B02CE68EQ58561585-4089F486-3526-4917-A14A-704D348ACED0Q58795622-B4526F08-302D-4FEE-8FDF-73AC3EFF3069Q63865741-35344C95-0B5B-4E9C-ADEF-D8C67467C5DAQ64071120-4CD7B742-DA01-4EB8-8580-F677910F4A93Q90913563-DA0FD569-5569-4393-A7E7-08C26F89545DQ90913577-B1282A23-DEBA-4897-9996-845F759C5F45Q91048669-F57D8B75-4655-460C-8384-2BF8412AD3CEQ91291801-A6BF9A7C-8A2C-4255-9171-11D104F13872Q91451450-C3B865F2-8F22-4DBC-A81D-F99EB469135EQ91676943-3CD3AFFD-E4E5-4DDB-ACCC-ACED69B75431Q95561225-B65BCB48-26D4-4BF5-A5FA-7A29726E9899
P50
description
researcher (ORCID 0000-0002-9765-2499)
@en
wetenschapper
@nl
name
Maria Esperanza Rodriguez-Ruiz
@en
Maria Esperanza Rodriguez-Ruiz
@nl
type
label
Maria Esperanza Rodriguez-Ruiz
@en
Maria Esperanza Rodriguez-Ruiz
@nl
prefLabel
Maria Esperanza Rodriguez-Ruiz
@en
Maria Esperanza Rodriguez-Ruiz
@nl
P31
P496
0000-0002-9765-2499